Search results for "MICROENVIRONMENT"

showing 10 items of 369 documents

Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation

2018

Abstract Tumor progression is a multifaceted process in which, complex interactions between tumor and different types of stromal cells and extracellular matrix components, actively contribute to its phenotypic heterogeneity. Among extracellular matrix proteins, secreted protein acidic and rich in cysteine (SPARC) has been deeply studied since conflicting reports have described its expression to be either increased or decreased in different cancer settings, also depending on whether it is produced by the neoplasm or by the neighboring stroma. Nevertheless, the different contribution of tumor- or stromal-derived SPARC in prostate tumor microenvironment has not been addressed at least for tumo…

Cancer ResearchTumor microenvironmentStromal cellCancerBiologymedicine.diseaseNeuroendocrine differentiationProstate cancerOncologyTumor progressionmedicineCancer researchAdenocarcinomaTrampCancer Research
researchProduct

Abstract A02: Neuroblastoma patient-derived orthotopic xenografts: Clinically relevant models for drug testing

2016

Abstract Widespread metastasis is a major problem for the treatment of high-risk neuroblastoma. Relevant neuroblastoma animal models are hence needed to study and target high-risk metastatic neuroblastoma. We developed neuroblastoma patient-derived orthotopic xenografts (PDXs) using viably cryopreserved or fresh patient neuroblastoma fragments which were implanted orthotopically into immunodeficient NSG mice. Immunohistochemistry showed that PDXs retain neuroblastoma markers and a highly infiltrative growth pattern. Importantly, we found distant metastasis to lungs, liver and bone marrow. Single nucleotide polymorphism array analysis confirmed that PDXs maintain patient-specific chromosomal…

Cancer ResearchPathologymedicine.medical_specialtyTumor microenvironmentOncogenebusiness.industryCancermedicine.diseasePediatric cancerMetastasisLymphatic systemmedicine.anatomical_structureOncologyNeuroblastomamedicineBone marrowbusinessCancer Research
researchProduct

Novel Approaches for Glioblastoma Treatment: Focus on Tumor Heterogeneity, Treatment Resistance, and Computational Tools

2019

BACKGROUND: Glioblastoma (GBM) is a highly aggressive primary brain tumor. Currently, the suggested line of action is the surgical resection followed by radiotherapy and treatment with the adjuvant temozolomide (TMZ), a DNA alkylating agent. However, the ability of tumor cells to deeply infiltrate the surrounding tissue makes complete resection quite impossible, and in consequence, the probability of tumor recurrence is high, and the prognosis is not positive. GBM is highly heterogeneous and adapts to treatment in most individuals. Nevertheless, these mechanisms of adaption are unknown. RECENT FINDINGS: In this review, we will discuss the recent discoveries in molecular and cellular heterog…

Cancer Researchmedicine.medical_treatmentDNA Mutational AnalysisBrain tumorBioinformaticsComplete resectionTumor heterogeneityCancer VaccinesMicrotubulesArticleClonal EvolutionMachine LearningGenetic HeterogeneityCancer stem cellAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineHumansTreatment resistancePrecision MedicineDNA Modification MethylasesImmune Checkpoint InhibitorsTemozolomideModels Geneticbusiness.industryBrain NeoplasmsTumor Suppressor ProteinsBrainComputational BiologyChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadiation therapyDNA Repair EnzymesOncologyDrug Resistance NeoplasmMutationTumor Suppressor Protein p53businessGlioblastomaGlioblastomamedicine.drug
researchProduct

Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden

2018

Goodpasture antigen-binding protein (GPBP) is an exportable1 Ser/Thr kinase that induces collagen IV expansion and has been associated with chemoresistance following epithelial-to-mesenchymal transition (EMT). Here we demonstrate that cancer EMT phenotypes secrete GPBP (mesenchymal GPBP) which displays a predominant multimeric oligomerization and directs the formation of previously unrecognized mesh collagen IV networks (mesenchymal collagen IV). Yeast two-hybrid (YTH) system was used to identify a 260SHCIE264 motif critical for multimeric GPBP assembly which then facilitated design of a series of potential peptidomimetics. The compound 3-[4''-methoxy-3,2'-dimethyl-(1,1';4',1'')terphenyl-2'…

0301 basic medicineTumor microenvironmentChemistryKinaseMesenchymal stem cellEMTPhenotype03 medical and health sciences030104 developmental biologyOncologyGPBPPrecursor cellCancer cellCancer researchmedicinecollagen IVtumor microenvironmentDoxorubicinSecretiondrug-resistant cancermedicine.drugResearch PaperOncotarget
researchProduct

Vascular Meets of Localized Hyperthermia

2008

When hyperthermia is applied in vitro, no fundamental differences can be seen between the response to normal and tumor cells. In vivo however, selective damage of tumor cells can be achieved and this phenomenon can be largely attributed to a number of characteristic properties of the blood vessels within solid tumors. Changes in blood flow induced by hyperthermia can influence the response of a tumor to heat either by affecting the delivery of heat through changes in heat dissipation or by a modulation of the tumor microenvironment which may in turn affect the thermosensitivity of tumor cells. Studies in experimental and human tumors suggest however that an accurate prediction of changes in…

HyperthermiaChemotherapyTumor microenvironmentbusiness.industrymedicine.medical_treatmentHyperthermia TreatmentPhotodynamic therapyBlood flowmedicine.diseaseRadiation therapyIn vivoImmunologyCancer researchMedicinebusiness
researchProduct

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

2020

The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remains unknown. Here, we investigated molecular hallmarks of circulating tumor cells (CTCs) to identify the events leading to myeloma trafficking into the bloodstream. After using next-generation flow to isolate matched CTCs and BM tumor cells from 32 patients, we found high correlation in gene expression at single-cell and bulk levels (r ≥ 0.94, P = 10−16), with only 55 genes differentially expressed between CTCs and BM tumor cells. CTCs overexpressed genes involved in inflammation, hypoxia, or epithelial–mesenchymal transition, whereas genes related with proliferation were downregulated in CTCs…

0301 basic medicineCancer ResearchEpithelial-Mesenchymal TransitionTranscription GeneticGene ExpressionBiologycirculating tumor cell03 medical and health sciences0302 clinical medicineCirculating tumor cellBone MarrowCell MovementCancer stem cellCell Line TumorTumor MicroenvironmentmedicineHumansHypoxiaMultiple myelomaCell ProliferationInflammationGene knockdownliquid biopsyCD44CENPFHematologyNeoplastic Cells CirculatingPrognosismedicine.disease3. Good healthmultiple myeloma030104 developmental biologymedicine.anatomical_structureOncologyCell culture030220 oncology & carcinogenesisNeoplastic Stem CellsCancer researchbiology.proteinBone marrow
researchProduct

Oxidative stress and antioxidants in the pathophysiology of malignant melanoma.

2018

Abstract The high number of somatic mutations in the melanoma genome associated with cumulative ultra violet (UV) exposure has rendered it one of the most difficult of cancers to treat. With new treatment approaches based on targeted and immune therapies, drug resistance has appeared as a consistent problem. Redox biology, including reactive oxygen and nitrogen species (ROS and RNS), plays a central role in all aspects of melanoma pathophysiology, from initiation to progression and to metastatic cells. The involvement of melanin production and UV radiation in ROS/RNS generation has rendered the melanocytic lineage a unique system for studying redox biology. Overall, an elevated oxidative st…

0301 basic medicineBiochemistry & Molecular BiologyClinical Biochemistrymedicine.disease_causeBiochemistryAntioxidantsMelanin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedicineAnimalsHumanstumor microenvironmentEpigeneticsmetastasesMolecular BiologyMelanomaReactive nitrogen specieschemistry.chemical_classificationreactive oxygen speciesReactive oxygen speciesTumor microenvironmentskin cancerbusiness.industryMelanomaintracellular redox statemedicine.diseaseOxidative Stress030104 developmental biologyreactive nitrogen specieschemistry030220 oncology & carcinogenesisCancer researchBiochemistry and Cell BiologySkin cancerbusinessOxidation-ReductionOxidative stressSignal Transduction
researchProduct

Human leukocyte elastase counteracts matrix metalloproteinase-7 induced apoptosis resistance of tumor cells.

2008

Matrix metalloproteinase-7 (MMP-7/Matrilysin) is a component of the tumor microenvironment associated with malignant progression. Its expression in tumors protects tumor cells from CD95-mediated apoptosis and the cytotoxic activity of tumor specific CD8(+) T cells. In the present study, we show that human leukocyte elastase (HLE) secreted by polymorphonuclear leukocytes cleaves MMP-7 resulting in loss of enzymatic activity. The anti-apoptotic effect of MMP-7 is reduced in the presence of HLE for CD95-, doxorubicin- and CTL-mediated apoptosis. Our data indicates that HLE may be a natural inactivator of MMP-7 which can counteract MMP-7-induced apoptosis resistance.

Cancer ResearchTumor microenvironmentbiologyChemistryNeutrophilsApoptosisMatrix metalloproteinaseFas receptorCell biologyOncologyApoptosisDoxorubicinNeutrophil elastaseMatrix Metalloproteinase 7NeoplasmsCancer researchbiology.proteinCytotoxic T cellHumanssense organsMatrilysinLeukocyte ElastaseCD8Cells CulturedT-Lymphocytes CytotoxicCancer letters
researchProduct

Integrating the Tumor Microenvironment into Cancer Therapy

2020

© 2020 by the authors.

0301 basic medicineCancer ResearchMechanotransductionReviewGut floralcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemStromamedicineMechanotransductionStromal reprogrammingTumor microenvironmentbiologybusiness.industryMicrobiotaCancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasebiology.organism_classificationPrognostic toolsMetforminMitochondria030104 developmental biologyMetabolismOncologyImmune therapyTumor progression030220 oncology & carcinogenesisCancer researchBiomarker discoverybusinessReprogrammingVitamin D3
researchProduct

Harnessing dendritic cells in cancer.

2011

Dendritic cells (DCs) are central to the initiation of tumor-specific immune responses. However, the tumor microenvironment generates immunosuppressive cells and soluble mediators that compromise DC functions and limit the success of DC-based therapies. Progress in understanding DC metabolism in cancer is uncovering novel therapeutic targets that could restore DC capacity to prime T cells and trigger effective anticancer responses. Accumulating evidence also indicates that conventional chemo- and radiotherapy protocols can cause DC activation, enhance antigen cross-presentation, selectively eliminate immunosuppressive cells and revert the immunosuppression state caused by cancer, suggesting…

medicine.medical_treatmentT-LymphocytesImmunologyAntineoplastic AgentsBiologyLymphocyte ActivationCancer VaccinesImmune systemAntigenChemoimmunotherapyAntigens NeoplasmNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyAnimalsHumansTumor microenvironmentInnate immune systemCancerImmunotherapyDendritic CellsAcquired immune systemmedicine.diseaseCell biologyKiller Cells NaturalDisease Models AnimalImmunotherapySeminars in immunology
researchProduct